TAIRX, INC.
Update：2026/11/10
Industries
Main Industry
Health Care
Main Product/Service
1. CVM-1118 (Foslinanib)
2. Zelnite®
3. TRX-NOC
4. TRX-920
5. TRX-105
2. Zelnite®
3. TRX-NOC
4. TRX-920
5. TRX-105
The content above was translated by Ai
Founded Year
2011
Unified Business No.
53529570
Status
Active
Number of Employees
0
Total Paid-in
Capital
1,121,199,080 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2017)
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
TaiRx is an efficient Pharma Management Corporate to develop a new generation of oncology molecule.TaiRx started a series of financing and expanded the drug pipeline. In addition to cancer treatment, TaiRx also extended our reach to the therapy of other major diseases. TaiRx has a rich product pipeline and many of our products are moving rapidlyinto various clinical stages to ensure the safety and efficacy of the drug products. TaiRx continues to search for novel cures for serious diseases and deliver them to the medical community to help those in need.
The content above was translated by Ai
